Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation

Author:

Ren Xiying12,Huang Qiusha12,Qu Qingyuan12,Cai Xuan12,Fu Haixia12,Mo Xiaodong12,Wang Yu12,Zheng Yawei3,Jiang Erlie3ORCID,Ye Yishan4,Luo Yi4,Chen Shaozhen5,Yang Ting5,Zhang Yuanyuan12,Han Wei12,Tang Feifei12,Mo Wenjian6,Wang Shunqing6ORCID,Li Fei7,Liu Daihong7,Zhang Xiaoying8,Zhang Yicheng8,Feng Shuqing9,Gao Feng9,Yuan Hailong10,Wang Dao11,Wan Dingming12,Chen Huan12,Chen Yao12,Wang Jingzhi12,Chen Yuhong12,Wang Ying13,Xu Kailin13ORCID,Lang Tao14,Wang Xiaomin14,Meng Hongbin15ORCID,Li Limin15,Wang Zhiguo16,Fan Yanling16,Chang Yingjun12,Xu Lanping12,Huang Xiaojun12,Zhang Xiaohui12ORCID

Affiliation:

1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China;

2. National Clinical Research Center for Hematologic Disease, Beijing, China;

3. Center of Hematopoietic Stem Cell Transplantation, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China;

4. Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;

5. Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China;

6. Department of Hematology, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, China;

7. Department of Hematology, Chinese PLA General Hospital, Beijing, China;

8. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;

9. Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan, China;

10. Hematology Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China;

11. Department of Pediatrics and

12. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;

13. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;

14. Department of Hematology, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China;

15. Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China; and

16. Bone Marrow Transplantation Department, Harbin Institute of Hematology and Oncology, Harbin, China

Abstract

Abstract Intracranial hemorrhage (ICH) is a rare but fatal central nervous system complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, factors that are predictive of early mortality in patients who develop ICH after undergoing allo-HSCT have not been systemically investigated. From January 2008 to June 2020, a total of 70 allo-HSCT patients with an ICH diagnosis formed the derivation cohort. Forty-one allo-HSCT patients with an ICH diagnosis were collected from 12 other medical centers during the same period, and they comprised the external validation cohort. These 2 cohorts were used to develop and validate a grading scale that enables the prediction of 30-day mortality from ICH in all-HSCT patients. Four predictors (lactate dehydrogenase level, albumin level, white blood cell count, and disease status) were retained in the multivariable logistic regression model, and a simplified grading scale (termed the LAWS score) was developed. The LAWS score was adequately calibrated (Hosmer-Lemeshow test, P > .05) in both cohorts. It had good discrimination power in both the derivation cohort (C-statistic, 0.859; 95% confidence interval, 0.776-0.945) and the external validation cohort (C-statistic, 0.795; 95% confidence interval, 0.645-0.945). The LAWS score is the first scoring system capable of predicting 30-day mortality from ICH in allo-HSCT patients. It showed good performance in identifying allo-HSCT patients at increased risk of early mortality after ICH diagnosis. We anticipate that it would help risk stratify allo-HSCT patients with ICH and facilitate future studies on developing individualized and novel interventions for patients within different LAWS risk groups.

Publisher

American Society of Hematology

Subject

Hematology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3